Vitamin D Supplementation Does Not Improve Asthma Treatment, Symptoms For Adults With Low Vitamin D Levels
EMBARGOED FOR EARLY RELEASE: 4 P.M. (CT) SUNDAY, MAY 18, 2014
Media Advisory: To contact corresponding author Tonya S. King, Ph.D., call Matthew Solovey at 717-531-0003, ext. 287127, or email email@example.com.
In adults with persistent asthma and low vitamin D levels, treatment with vitamin D3 did not reduce the rate of treatment failure or exacerbation of symptoms, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic Society International Conference.
In children and adults with asthma, lower vitamin D levels have been linked to impaired lung function, increased frequency of exacerbations, and reduced responsiveness to steroid therapy. Data suggesting that vitamin D supplementation could modify steroid response and reduce airway inflammation have led to questions about whether treatment with vitamin D might improve outcomes in patients with asthma, according to background information in the article.
Mario Castro, M.D., M.P.H., of the Washington University School of Medicine, St. Louis, and colleagues randomly assigned adults with asthma and low vitamin D levels to vitamin D3 (100,000 IU once, then 4,000 IU/daily for 28 weeks; n = 201) or placebo (n = 207), which was added to treatment with the inhaled corticosteroid ciclesonide.
The researchers found that the addition of vitamin D3 to ciclesonide did not significantly reduce the rate of first treatment failure (a composite outcome of decline in lung function and increases in use of beta-agonists, systemic steroids, and health care utilization) compared with placebo; 28 percent and 29 percent of participants in each group, respectively, experienced at least 1 treatment failure during 28 weeks. Participants most commonly experienced treatment failure due to the need for increased inhaled or systemic steroids (58 percent) or by experiencing an exacerbation of asthma symptoms (46 percent).
There was also no significant reduction in other measured outcomes related to asthma control, airway function, quality of life, or airway inflammation.
“These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma,” the authors conclude.
Editor’s Note: This study was conducted with the support of grants that were awarded by the National Heart, Lung, and Blood Institute. Ciclesonide and levalbuterol were provided without cost by Sunovion Pharmaceuticals Inc. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 4 p.m. CT Sunday, May 18 at this link.
We recently switched email servers. Please check your spam filters if you are no longer receiving our email news release packets. To ensure you always receive JAMA Network Media Relations emails, add the email address firstname.lastname@example.org to your address book.
The U.S. Preventive Services Task Force (USPSTF) has issued a recommendation statement regarding the use of statins for primary prevention of cardiovascular disease in adults. The report appears in the November 15 issue of JAMA. Recommendations — The USPSTF recommends initiating use of low- to moderate-dose statins in adults ages 40 to 75…
CHICAGO (October 6, 2016) — The JAMA Network has launched a new online platform. The new platform aims to make the sites more usable, discoverable and faster on any device. Please consult http://sites.jamanetwork.com/help for an introductory video and FAQs and send feedback to email@example.com # # # For more information, contact JAMA Network Media Relations at 312-464-JAMA…